Physician profile
Patrick Huan Le
NPI 1396312393
$5,730.38
in general payments reported to CMS, 2019-2025
11 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.77 · 2022: $401 · 2023: $1,008 · 2024: $3,546 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,979 · Travel and Lodging: $2,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.55 |
| Travel and Lodging | $2,266.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,184.99 | 2022-2024 | Envista Mx60 Iol, Stellaris Elite, Trulign Iol |
| Johnson & Johnson Surgical Vision, INC. | $1,199.06 | 2021-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Alcon Vision LLC | $562.68 | 2023-2025 | Hydrus Microstent, Clareon, Clareon Panoptix Pro |
| Sight Sciences, INC. | $294.00 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Abbvie INC. | $159.61 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $97.99 | 2023 | Quatera 700 |
| Rayner Intraocular Lenses Limited | $72.54 | 2024 | Omidria |
| Glaukos Corporation | $67.27 | 2024 | Idose |
| Carl Zeiss Meditec Cataract Technology INC. | $48.79 | 2022 | |
| Ocular Therapeutix, INC. | $22.74 | 2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $20.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.